{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:47:20Z","timestamp":1791262040528,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/wnf.0b013e318067e255","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T03:01:05Z","timestamp":1206414065000},"page":"104-119","source":"Crossref","is-referenced-by-count":34,"title":["Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders"],"prefix":"10.1097","volume":"31","author":[{"given":"Stephen I.","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Rosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mastropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrice D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke L.","family":"Gaskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2004.10.001","article-title":"Histone deacetylase inhibitors.","volume":"40","author":"Monneret","year":"2005","journal-title":"Eur J Med Chem"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpsyc.62.8.829","article-title":"Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia.","volume":"62","author":"Akbarian","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1139\/o05-041","article-title":"Role of histone acetylation in the control of gene expression.","volume":"83","author":"Verdone","year":"2005","journal-title":"Biochem Cell Biol"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2004.03.001","article-title":"Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics.","volume":"72","author":"Sharma","year":"2005","journal-title":"Schizophr Res"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deactylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-7-20210203","first-page":"10379","article-title":"Epigenetic mechanisms and gene networks in the nervous system J Neurosci.","volume":"25","author":"Colvis","year":"2005","journal-title":""},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.yfrne.2005.10.002","article-title":"Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat.","volume":"26","author":"Szyf","year":"2005","journal-title":"Front Neuroendocrinol"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2005.03040.x","article-title":"Histone deacetylase inhibitors decrease reelin promoter methylation in vitro.","volume":"93","author":"Mitchell","year":"2005","journal-title":"J Neurochem"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1073\/pnas.262658999","article-title":"An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.","volume":"99","author":"Tremolizzo","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"12580","DOI":"10.1074\/jbc.M511677200","article-title":"Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA.","volume":"281","author":"Ying","year":"2006","journal-title":"J Biol Chem"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/hmg\/ddh131","article-title":"Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.","volume":"13","author":"Minamiyama","year":"2004","journal-title":"Hum Mol Genet"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.","volume":"93","author":"Ryu","year":"2005","journal-title":"J Neurochem"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/258612a0","article-title":"Altered chromatin ultrastructure in neutrophils of schizophrenics.","volume":"258","author":"Issidorides","year":"1975","journal-title":"Nature"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0364-7722(78)90025-5","article-title":"Drug-induced changes in chromatin ultrastructure and nuclear basic proteins of the neutrophils of chronic schizophrenics.","volume":"2","author":"Issidorides","year":"1978","journal-title":"Prog Neuropsychopharmacol"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajmg.1320600209","article-title":"Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia.","volume":"60","author":"Kosower","year":"1995","journal-title":"Am J Med Genet"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.0505394102","article-title":"Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.","volume":"102","author":"Dong","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.pnpbp.2006.04.007","article-title":"Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of Alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications.","volume":"30","author":"Deutsch","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1073\/pnas.0409665102","article-title":"In psychosis, cortical interneurons overexpress DNA-methyltransferase 1.","volume":"102","author":"Veldic","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1073\/pnas.0510341103","article-title":"The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.","volume":"103","author":"Simonini","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1523\/JNEUROSCI.0589-04.2004","article-title":"Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures.","volume":"24","author":"Tsankova","year":"2004","journal-title":"J Neurosci"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nn1659","article-title":"Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action.","volume":"9","author":"Tsankova","year":"2006","journal-title":"Nat Neurosci"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.neuron.2004.05.021","article-title":"Chromatin acetylation, memory, and LTP are impaired in CBP mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.","volume":"42","author":"Alarcon","year":"2004","journal-title":"Neuron"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jcp.1040860511","article-title":"Regulation of growth and morphological modulation of HeLa65 cells in monolayer culture by dibutyryl cyclic AMP, butyrate and their analogs.","volume":"86","author":"Ghosh","year":"1975","journal-title":"J Cell Physiol"},{"key":"R29-7-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1242\/jcs.21.2.391","article-title":"Ultrastructural and enzymic modulation of HeLa cells induced by sodium butyrate and the effects of cytochalasin B and colcemid.","volume":"21","author":"Deutsch","year":"1976","journal-title":"J Cell Sci"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200803000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:28Z","timestamp":1786035328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200803000-00007"}},"subtitle":["Ready for Prime Time?"],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318067e255","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}